ecancermedicalscience

Review

Repurposing of drugs for triple negative breast cancer: an overview

13 Jul 2020
Andrea Spini, Sandra Donnini, Pan Pantziarka, Sergio Crispino, Marina Ziche

Breast cancer (BC) is the most frequent cancer among women in the world and it remains a leading cause of cancer death in women globally. Among BCs, triple negative breast cancer (TNBC) is the most aggressive, and for its histochemical and molecular characteristics is also the one whose therapeutic opportunities are most limited. The REpurposing Drugs in Oncology (ReDO) project investigates the potential use of off patent non-cancer drugs as sources of new cancer therapies. Repurposing of old non-cancer drugs, clinically approved, off patent and with known targets into oncological indications, offers potentially cheaper effective and safe drugs. In line with this project, this article describes a comprehensive overview of preclinical or clinical evidence of drugs included in the ReDO database and/or PubMed for repurposing as anticancer drugs into TNBC therapeutic treatments.

Article metrics: 891 views
436
455

Related Articles

Zohre Momenimovahed, Azita Tiznobaik, Safoura Taheri, Soheil Hassanipour, Hamid Salehiniya
Lotfi Kochbati, Verna Vanderpuye, Rim Moujahed, Mouna Ben Rejeb, Zeineb Naimi, Tajudeen Olasinde
Lekha Madhavan Nair, KM Jagathnath Krishna, Aswin Kumar, Susan Mathews, John Joseph, Francis Vadakkumparambil James
Josephine Nsaful, Verna Vanderpuye, Aba Anoa Scott, Florence Dedey, Samuel A Oppong, Rita Appiah-Danquah, Nelson Damale, Benjamin Fenu, Theodore Wordui, Joel Yarney, Joe Nat Clegg-Lamptey
Rima A Abdul-Khalek, Ghassan Abu-Sitta, Nassim El Achi, Walaa Kayyal, Ahmad Elamine, Aba Noubani, Marilyne Menassa, Fahad Ahmed, Richard Sullivan, Deborah Mukherji
Paola Zagami, Eleni Kandaraki, Giuseppe Renne, Franco Grimaldi, Francesca Spada, Alice Laffi, Nicola Fazio